2021
DOI: 10.1007/s12288-020-01391-9
|View full text |Cite
|
Sign up to set email alerts
|

Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 18 publications
0
5
0
Order By: Relevance
“…Interestingly, despite the extra-nodal nature of PG-DLBCL, it can often be of a GCB cell of origin and is unlikely to present with MYD88 mutations. [6][7][8] A non-GCB cell of origin and the presence of MYD88 mutations are features known to be associated with inferior survival, and frequently found within large B-cell lymphoma of immune-privileged sites. 8,25,26 It is important to note that while we did not perform molecular profiling, 51% of patients in our study were of a GCB cell of origin.…”
Section: -85 71-100mentioning
confidence: 99%
See 1 more Smart Citation
“…Interestingly, despite the extra-nodal nature of PG-DLBCL, it can often be of a GCB cell of origin and is unlikely to present with MYD88 mutations. [6][7][8] A non-GCB cell of origin and the presence of MYD88 mutations are features known to be associated with inferior survival, and frequently found within large B-cell lymphoma of immune-privileged sites. 8,25,26 It is important to note that while we did not perform molecular profiling, 51% of patients in our study were of a GCB cell of origin.…”
Section: -85 71-100mentioning
confidence: 99%
“…[3][4][5] According to the Hans algorithm, both a germinal centre B (GCB) cell and non-GCB cell of origin have been described, with no definitive subtype predominanting. [6][7][8][9] Further, a third will have a simultaneous low-grade component, raising the possibility of large cell transformation. 1 Historically, gastrectomy was performed; however, the contemporary approach to treatment is aligned with that of primary extra-nodal DLBCL and comprises chemoimmunotherapy with or without radiotherapy.…”
Section: Introductionmentioning
confidence: 99%
“… 5 At present, R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)‐like therapies represent the standard therapeutic protocol in the majority of patients, especially in people at advanced stages. 6 …”
Section: Introductionmentioning
confidence: 99%
“…The current treatments for PGI‐DLBCL involve chemotherapy, radiotherapy, surgery, and double or triple combination therapies mentioned above 5 . At present, R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)‐like therapies represent the standard therapeutic protocol in the majority of patients, especially in people at advanced stages 6 …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation